Indocyanine Green-Labeled Antibody-NOTCH2 as a New Fluorescent Molecular Imaging Probe for Gastric Cancer
Gastric cancer is a malignant tumor that seriously threatens human health. Its high mortality is mainly due to delayed diagnosis, which makes early detection important for improving patient prognosis. Near-infrared (NIR) fluorescence imaging, with its high signal-to-noise ratio and good sensitivity, has been widely applied in biomedical research and clinical diagnosis. NOTCH2 is often overexpressed in gastric cancer and may serve as a useful target for diagnosis and treatment. In this study, we constructed a NOTCH2-targeted single-chain variable fragment (scFv) conjugated with indocyanine green (ICG) and evaluated its application in gastric cancer imaging in vitro and in vivo. The ICG-scFv probe showed similar photophysical properties to free ICG and was specifically taken up by MKN45 gastric cancer cells. In NIR imaging, ICG-scFv selectively accumulated in tumor tissue, achieved tumor-specific imaging, and maintained fluorescence signals for a longer time, which was further confirmed by colocalization analysis. These results indicate that the targeted fluorescent probe ICG-scFv may have potential value in the diagnosis and treatment of gastric cancer.
Authors
- Yumin Li
- Qinan Li
- Lüxi Yang (ORCID: https://orcid.org/0000-0003-1474-1806)
- Jinglan Wang
- Mei Li (ORCID: https://orcid.org/0000-0002-4303-5962)
- Xiaoxia Zhang (ORCID: https://orcid.org/0000-0001-5270-6775)
- Tao Liu (ORCID: https://orcid.org/0000-0003-1573-6777)
- Wenting He (ORCID: https://orcid.org/0009-0008-4718-4114)
Institutions
- Gansu Provincial Hospital (CN)
- Lanzhou University Second Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Bioconjugate Chemistry
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1021/acs.bioconjchem.5c00465
- Citations
- 1
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.67